Ireland - Financial Media Contact
Powerscourt
Tel: +353 (0)1 536 0682
November 2024 Circular (including Notice of EGM)
RNS Announcements
Investee Companies
Wed, 08 Jan 2025
Update re Poseida Transaction
Tue, 26 Nov 2024
Poseida to be Acquired and Update on Tender Offer
Tue, 12 Nov 2024
Proposed Tender Offer
Mon, 04 Nov 2024
Block listing Interim Review
Thu, 26 Sep 2024
Result of EGM
News Archive>
11 Dec 2024
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
07 Nov 2024
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
24 Oct 2024
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema
17 Oct 2024
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
27 Sep 2024
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
